Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Phase 1 Unknown 16 enrolled ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

NaSequentialOpen-labelTreatment

Summary

This is a single arm, open label, multi-center and fist in human dose escalation study, to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced and metastatic solid tumor.

Timeline

Start: 2022-06-15
Primary completion: 2023-08-30
Completion: 2024-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMM27M	Monoclonal antibody	0.1 mg/kg	Other
Subject	IMM27M	Monoclonal antibody	0.3 mg/kg	Other
Subject	IMM27M	Monoclonal antibody	1 mg/kg	Other
Subject	IMM27M	Monoclonal antibody	2 mg/kg	Other
Subject	IMM27M	Monoclonal antibody	3 mg/kg	Other

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Summary

Timeline

Drugs

Indications